Bluepharma
Private Company
Total funding raised: $65M
Overview
Bluepharma is a private Portuguese pharmaceutical group founded in 2001, built on the acquisition of a former Bayer plant. It has evolved from a manufacturing operation into an integrated CRDMO with over 650 employees, 20 innovative group companies, and a strong export focus (89% export rate). The company's core business spans R&D, contract development and manufacturing (CDMO) for high-potency products, and the commercialization of its own portfolio, supported by proprietary technologies like BlueOS® and ONConcept®.
Technology Platform
Proprietary drug delivery system (BlueOS®) and specialized manufacturing platform for high-potency/complex products (ONConcept®).
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Bluepharma competes in the European and global CDMO space against larger players like Lonza, Catalent, and Recipharm, as well as regional specialists. Its differentiation lies in its integrated 'R&D to market' model, proprietary drug delivery technologies, specialized high-potency capabilities, and its position as a cost-competitive EU-based manufacturer with strong regulatory credentials.